Ipamorelin Research: Growth Hormone Secretagogue Studies

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that has gained significant attention in preclinical research. Classified as a selective growth hormone releasing peptide (GHRP), Ipamorelin is distinguished from other GHS compounds by its selectivity profile in laboratory studies.

With the amino acid sequence Aib-His-D-2Nal-D-Phe-Lys-NH2, Ipamorelin has a molecular weight of approximately 711.85 Da. Its synthetic design allows for targeted receptor interaction studies in preclinical models.

Mechanism of Action in Research Models

GHS Receptor Interaction

In-vitro receptor binding studies have demonstrated that Ipamorelin interacts with the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Unlike broader-acting GHS compounds, preclinical research suggests that Ipamorelin demonstrates a more selective binding profile, which has made it valuable for receptor specificity studies.

Selectivity Profile

A distinguishing feature of Ipamorelin in research is its reported selectivity. Laboratory studies have indicated that, compared to other GHS peptides like GHRP-6 or GHRP-2, Ipamorelin may demonstrate reduced interaction with ACTH and cortisol pathways. This selectivity makes it a useful tool for isolating GH-specific effects in experimental models.

Research Applications

Growth Hormone Secretion Studies

Preclinical research has utilized Ipamorelin extensively in studies examining growth hormone secretion dynamics. In-vitro pituitary cell models have been used to characterize its secretagogue activity and compare it with other GHS compounds.

Bone Density Research Models

Laboratory studies have investigated Ipamorelin’s potential effects in bone cell models. Preclinical research examining osteoblast activity and bone mineralization assays has contributed to a growing body of literature on GHS peptides and skeletal research.

Combined GH Research Protocols

Researchers frequently study Ipamorelin alongside CJC-1295 Without DAC (also known as Modified GRF 1-29). The CJC-1295/Ipamorelin blend is a popular research combination, as the two peptides act through different receptor pathways — GHRH receptor and GHS receptor respectively — allowing for multi-pathway investigation.

Comparison with Other Growth Hormone Secretagogues

Ipamorelin vs. GHRP-6

In laboratory comparisons, Ipamorelin has demonstrated differences from GHRP-6 in terms of receptor selectivity profiles. Research suggests Ipamorelin may have a narrower activity spectrum.

Ipamorelin vs. Hexarelin

Hexarelin represents another GHS peptide studied alongside Ipamorelin. Comparative in-vitro studies have characterized differences in potency and selectivity between these compounds.

Handling and Experimental Considerations

For research applications, Ipamorelin should be:

  • Stored lyophilized at -20°C
  • Reconstituted with appropriate sterile diluent
  • Protected from repeated freeze-thaw cycles
  • Used within validated stability windows

Conclusion

Ipamorelin remains one of the most studied growth hormone secretagogues in preclinical research. Its selectivity profile, ease of use in laboratory settings, and extensive published literature make it a valuable research tool. Molecular Peptides offers Ipamorelin (10mg) with full analytical documentation for research applications.

Disclaimer: All products are sold strictly for in-vitro research purposes only. Not for human consumption. The information provided is for educational and research reference only and does not constitute medical advice.

Stay Updated

Subscribe for exclusive deals, new product alerts, and research updates.

Newsletter Signup - Popup

By subscribing, you agree to receive marketing emails from Molecular Peptides. You can unsubscribe at any time.